TRDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TRDA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is still digesting a major clinical disappointment, analyst sentiment has turned more cautious, insider selling is rising sharply, and the technical setup remains weak despite a small daily bounce. For an impatient investor who does not want to wait for a better entry, this is still not an attractive long-term purchase today.
TRDA is in a bearish primary trend: SMA_200 is above SMA_20, and SMA_20 is above SMA_5, which signals ongoing downside pressure. MACD histogram is slightly positive at 0.0866 and expanding, so short-term momentum has improved a bit, but RSI_6 at 45.3 is still neutral and does not confirm a strong rebound. Price at 6.79 is near resistance at 6.798, with the next resistance at 7.1; support sits at 6.309 and then 5.82. The recent pattern estimate also points to negative drift over the next day, week, and month, which supports a cautious-to-bearish stance.
["Oppenheimer raised its price target to $23 from $21 and kept an Outperform rating on 2026-04-06.", "Cantor Fitzgerald initiated coverage with an Overweight rating on 2026-04-01.", "MACD histogram is positive and expanding, showing some short-term momentum recovery.", "The stock is trading near near-term resistance, so any positive trial surprise could trigger a sharp bounce."]
["Topline ELEVATE-44-201 results on 2026-05-07 were disappointing, with only a 2.36% increase in dystrophin production.", "The stock fell 57.27% after the trial readout, indicating severe investor repricing.", "Roth Capital cut its price target to $10 from $19 and kept Buy, but explicitly cited lackluster dystrophin expression.", "H.C. Wainwright downgraded the stock to Neutral from Buy after underwhelming initial cohort data.", "Pomerantz LLP announced investigations and potential class action activity on 2026-05-26 and 2026-05-28, adding legal overhang.", "Insiders are selling, with selling amount increasing 1842.13% over the last month.", "Bearish moving averages remain intact and the stock trend model points to further downside over the next month."]
No usable latest-quarter financial snapshot was provided, so there is no reliable revenue or earnings trend to assess here. Based on the data available, the story is still dominated by clinical-stage execution rather than operating financial performance, and the latest quarter season cannot be confirmed from the provided information.
Analyst sentiment is mixed but has recently deteriorated. Earlier in April, Oppenheimer and Cantor were constructive, with Oppenheimer raising its target and Cantor initiating Overweight. After the disappointing May 7 clinical results, sentiment weakened: Roth Capital cut its target sharply to $10 from $19 while keeping Buy, and H.C. Wainwright downgraded to Neutral. Overall, Wall Street still sees potential in the platform, but the pros view is now much more cautious and highly dependent on future data, while the cons view is that current efficacy results are not competitive enough.
